Tamiflu Isn’t the Only Flu Treatment Available

As flu activity increases nationwide, a recent article highlights that Tamiflu is not the only CDC-recommended antiviral available to treat influenza. Other options—Xofluza, Relenza, and Rapivab—offer different dosing, delivery methods, and age approvals, which may influence treatment decisions based on access, cost, and patient needs. Antivirals are most effective when started within two days of symptom onset, underscoring the importance of timely testing and care-seeking.

The article also notes growing use of Xofluza due to single-dose convenience and fewer reported side effects, alongside ongoing considerations around availability, insurance coverage, and antiviral resistance—key context for public health communicators sharing accurate, actionable flu guidance this season. Read it from CNN here.